The impact of okra on metabolic parameters in Type 2 diabetes patients: Results from a double-blind clinical trial

IF 1.7 Q2 Medicine

Advances in integrative medicine Pub Date : 2025-03-08 DOI:10.1016/j.aimed.2025.03.004

Ali Hesamzadeh , Zahra Kashi , Adeleh Bahar , Majid Saeidi , Atena Ramzani , Reza Ali Mohamadpour Tahmtan

{"title":"The impact of okra on metabolic parameters in Type 2 diabetes patients: Results from a double-blind clinical trial","authors":"Ali Hesamzadeh , Zahra Kashi , Adeleh Bahar , Majid Saeidi , Atena Ramzani , Reza Ali Mohamadpour Tahmtan","doi":"10.1016/j.aimed.2025.03.004","DOIUrl":null,"url":null,"abstract":"<div><h3>Introduction</h3><div>Okra (Abelmoschus esculentus), a plant with a historical background in medicinal applications, exhibits potential antidiabetic properties through mechanisms that affect sugar absorption and insulin sensitivity. This study investigates the impact of okra on glycemic control in patients with Type 2 diabetes mellitus (T2DM).</div></div><div><h3>Methods</h3><div>This double-blind, placebo-controlled, multi-center study assessed the impact of okra capsules on glycemic control in 53 patients with T2DM. Data, including demographic characteristics and metabolic parameters, were collected at baseline and after 60 days. Dietary and physical activity questionnaires were employed to control for confounding variables. Data analysis was conducted using descriptive and analytical tests, as appropriate, to compare baseline and post-intervention values both between and within groups. A statistical significance level of p < 0.05 was established.</div></div><div><h3>Results</h3><div>In the intervention group, 70.04 % were female (vs. 84.6 % in the control group), with mean ages of 53.41 ± 6.36 and 52.73 ± 8.69 years, respectively. No significant demographic differences were found (p > 0.05). Insulin levels increased significantly in the intervention group (5.09 ± 4.55–7.43 ± 6.78, p < 0.05), as did HOMA-IR (1.94 ± 1.86–2.96 ± 2.74, p < 0.05), while HbA1c remained unchanged (7.57 ± 1.23–7.94 ± 1.00, p > 0.05). No significant changes were observed in BMI, FBS, BUN, creatinine, triglycerides, or liver enzymes (p > 0.05).</div></div><div><h3>Conclusion</h3><div>The results do not position okra as a primary treatment, they suggest the need for further investigation in larger, longer-term studies to explore its role in T2DM management. This highlights okra's potential as a complementary treatment and underscores the importance of a multifaceted approach in health care, focusing on patient education, research involvement, monitoring metabolic parameters, and interdisciplinary collaboration.</div></div>","PeriodicalId":7343,"journal":{"name":"Advances in integrative medicine","volume":"12 4","pages":"Article 100474"},"PeriodicalIF":1.7000,"publicationDate":"2025-03-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Advances in integrative medicine","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2212958825000333","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction

Okra (Abelmoschus esculentus), a plant with a historical background in medicinal applications, exhibits potential antidiabetic properties through mechanisms that affect sugar absorption and insulin sensitivity. This study investigates the impact of okra on glycemic control in patients with Type 2 diabetes mellitus (T2DM).

Methods

This double-blind, placebo-controlled, multi-center study assessed the impact of okra capsules on glycemic control in 53 patients with T2DM. Data, including demographic characteristics and metabolic parameters, were collected at baseline and after 60 days. Dietary and physical activity questionnaires were employed to control for confounding variables. Data analysis was conducted using descriptive and analytical tests, as appropriate, to compare baseline and post-intervention values both between and within groups. A statistical significance level of p < 0.05 was established.

Results

In the intervention group, 70.04 % were female (vs. 84.6 % in the control group), with mean ages of 53.41 ± 6.36 and 52.73 ± 8.69 years, respectively. No significant demographic differences were found (p > 0.05). Insulin levels increased significantly in the intervention group (5.09 ± 4.55–7.43 ± 6.78, p < 0.05), as did HOMA-IR (1.94 ± 1.86–2.96 ± 2.74, p < 0.05), while HbA1c remained unchanged (7.57 ± 1.23–7.94 ± 1.00, p > 0.05). No significant changes were observed in BMI, FBS, BUN, creatinine, triglycerides, or liver enzymes (p > 0.05).

Conclusion

The results do not position okra as a primary treatment, they suggest the need for further investigation in larger, longer-term studies to explore its role in T2DM management. This highlights okra's potential as a complementary treatment and underscores the importance of a multifaceted approach in health care, focusing on patient education, research involvement, monitoring metabolic parameters, and interdisciplinary collaboration.

查看原文本刊更多论文

秋葵对2型糖尿病患者代谢参数的影响：一项双盲临床试验的结果

秋葵（Abelmoschus esculentus）是一种具有药用背景的植物，通过影响糖吸收和胰岛素敏感性的机制显示出潜在的抗糖尿病特性。本研究探讨了秋葵对2型糖尿病（T2DM）患者血糖控制的影响。方法采用双盲、安慰剂对照、多中心研究评估秋葵胶囊对53例T2DM患者血糖控制的影响。在基线和60天后收集数据，包括人口统计学特征和代谢参数。采用饮食和体育活动问卷控制混杂变量。酌情使用描述性和分析性测试进行数据分析，以比较各组之间和组内的基线值和干预后值。p <； 0.05的差异有统计学意义。结果干预组患者中女性占70.04 %（对照组为84.6 %），平均年龄分别为53.41 ± 6.36岁和52.73 ± 8.69岁。统计学差异无统计学意义（p >； 0.05）。在干预组胰岛素水平显著增加(5.09 ±4.55 - -7.43  ± 6.78,p & lt; 0.05),HOMA-IR一样(1.94 ±1.86 - -2.96  ± 2.74,p & lt; 0.05),而糖化血红蛋白保持不变( 7.57±1.23 - -7.94  ± 1.00,p 祝辞 0.05)。BMI、FBS、BUN、肌酐、甘油三酯或肝酶均无显著变化（p >； 0.05）。结论：该结果并未将秋葵定位为主要治疗药物，他们建议需要进一步开展更大规模、更长期的研究，以探索其在T2DM管理中的作用。这突出了秋葵作为一种补充治疗的潜力，并强调了在医疗保健中采用多方面方法的重要性，重点是患者教育、研究参与、监测代谢参数和跨学科合作。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Advances in integrative medicine INTEGRATIVE & COMPLEMENTARY MEDICINE-

CiteScore

3.20

自引率

11.80%

发文量

审稿时长

15 weeks

期刊介绍： Advances in Integrative Medicine (AIMED) is an international peer-reviewed, evidence-based research and review journal that is multi-disciplinary within the fields of Integrative and Complementary Medicine. The journal focuses on rigorous quantitative and qualitative research including systematic reviews, clinical trials and surveys, whilst also welcoming medical hypotheses and clinically-relevant articles and case studies disclosing practical learning tools for the consulting practitioner. By promoting research and practice excellence in the field, and cross collaboration between relevant practitioner groups and associations, the journal aims to advance the practice of IM, identify areas for future research, and improve patient health outcomes. International networking is encouraged through clinical innovation, the establishment of best practice and by providing opportunities for cooperation between organisations and communities.